Axion Biosystems has raised $6 million to back its Maestro multiwell microelectrode array platform, a high-throughput system for cellular analysis that enables researchers to recreate complex, active systems such as brain activity and heartbeats. It's life sciences instrumentation that's used for testing including drug safety, drug discovery, and disease modeling. The cash will go to growing the Atlanta, GA-based company's product line. "Axion's products are being adopted around the world at an ever-increasing rate," said CEO Tom O'Brien in a statement. "To maintain our rapid growth, we need to further invest in our global sales channel and in the support system for our expanding list of customers in pharma, biotech, academia and government." Release
> Existing partners Olympus Respiratory America, a subsidiary of Olympus, and Vida Diagnostics have expanded their collaboration to incorporate precision informatics into current and future diagnostic and therapeutic procedural workflows to manage pulmonary disease patients. More
> Enzo Biochem ($ENZ) will receive $35 million from Thermo Fisher ($TMO) subsidiary Life Technologies for a settlement in a patent infringement case in one of 11 cases originally brought. Four of these have been resolved, with 7 remaining pending. More
> Royal Philips ($PHG) will co-market a minimally invasive prostate cancer ablation system with Canadian company Profound Medical ($PRN). They will collaborate first in Europe, then in Canada, the U.S. and other markets as they gain regulatory clearances. More